Geniposide protects PC12 cells from lipopolysaccharide-evoked inflammatory injury via up-regulation of miR-145-5p

Abstract

Geniposide is an active ingredient with anti-apoptotic and anti-inflammatory properties. This study was to examine the effects of geniposide on a cell model of spinal cord injury (SCI). PC12 cells were administrated with geniposide before subjected to LPS. The effects of geniposide were analyzed by utilizing CCK-8 assay, apoptosis assay, ELISA, RT-qPCR and Western blot. We found that PC12 cells viability was unchanged by treating with geniposide. However, geniposide with concentrations of 200 or 300 μg/mL significantly mitigated LPS-evoked viability loss. Meanwhile, apoptosis driven by LPS was mitigated by geniposide, which accompanied with p53, Bax and cleaved caspase-3 down-regulation, and Bcl-2 up-regulation. Besides this, the expression and release of IL-1β, IL-6, IL-8 and TNF-α evoked by LPS were mitigated by geniposide. miR-145-5p was a target of geniposide. miR-145-5p expression was up-regulated by geniposide, and geniposide did not protect PC12 cells against LPS injury when miR-145-5p was silenced. Moreover, geniposide inhibited NF-κB and JNK pathways via up-regulating miR-145-5p. In short, the present work described the neuroprotective effects of geniposide by targeting miR-145-5p. Further mechanisms involved in geniposide’s beneficial effects are correlated with the inhibited NF-κB and JNK pathways.

Highlights

1. Geniposide prevents LPS-induced injury in PC12 cells;

2. Geniposide up-regulates miR-145-5p;

3. Geniposide protects PC12 cells via up-regulation of miR-145-5p;

4. Geniposide inhibits NF-κB and JNK pathways via up-regulation of miR-145-5p.

Keywords:

• Geniposide
• spinal cord injury (SCI)
• lipopolysaccharide (LPS)
• PC12 cell
• miR-145-5p

View addendum:

Expression of Concern

Disclosure statement

No potential conflict of interest was reported by the authors.